Organovo (NASDAQ:ONVO) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Stock Performance

The stock has a market capitalization of $3.47 million, a PE ratio of -2.40 and a beta of 1.13. Organovo has a 52 week low of $1.56 and a 52 week high of $21.96. The stock’s fifty day simple moving average is $3.94 and its 200 day simple moving average is $4.54.

Organovo (NASDAQ:ONVO) last issued its earnings results on Wednesday, February 19th. The medical research company reported ($2.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.52) by $0.24. Organovo had a negative net margin of 10,151.64% and a negative return on equity of 346.26%. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.05 million. Research analysts predict that Organovo will post -0.77 EPS for the current fiscal year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.